08 February 2013 | News | By BioSpectrum Bureau
China Cord Blood (CCB) effective equity interest in Shandong Province Qilu Stem Cells Engineering increased from 19.9 percent to 24 percent
Singapore: China Cord Blood (CCB), which is the first and largest cord blood banking operator in China, highlighted that it has completed the previously announced transaction with Cordlife Services, a subsidiary of CCB's strategic affiliate. Cordlife is a cord blood and tissue banking services provider listed on the Australian Securities Exchange (ASX).
As a result of the transaction, CCB's effective equity interest in Shandong Province Qilu Stem Cells Engineering, the operator of the Shandong Cord Blood Bank, has increased from 19.9 percent-to-24 percent, further extending the company's presence in the Shandong market. The transaction was first announced on December 6, 2012.